#Hydromorphone antidote series

Bismuth, Hôpital Fernand Widal, Paris, Franceĭr R.E. Newcastle, Newcastle-upon Tyne, United Kingdom Bateman, Department of Clinical Pharmacology, University of WORKING GROUP ON VOLUME 1, EVALUATION OF ANTIDOTES Membersĭr D.N. ReferencesĪPPENDIX II Principles for the evaluation of antidotesĪPPENDIX III Proforma for monographs on antidotes for Pharmaceutical incompatibilities and drugĤ.13.5. Precautions and contraindications 4.13.4. Adverse effectsĤ.12.6.2 Interaction with calcium antagonistsĤ.12.7. Controversial issues and areas of insufficientĤ.12.5. Other consequential or supportive therapy 4.12.4. IndicationsĤ.12.1.1 Treatment of malignant hyperthermiaĤ.12.1.2 Treatment of neuroleptic malignantĤ.12.1.3 Treatment of hyperthermia induced byĤ.12.2.1 Treatment of severe drug-inducedĤ.12.2.2 Prophylaxis of malignant hyperthermiaĤ.12.3. Use in other drug-induced hyperthermia 4.12. Use in neuroleptic malignant syndrome 4.11.3. Use in malignant hyperthermiaĤ.11.1.1 Prophylaxis of malignant hyperthermiaĤ.11.1.2 Prophylaxis of malignant hyperthermiaĤ.11.2. Administration and plasma concentrations 4.9.2. PharmacodynamicsĤ.8.1.3 Studies in malignant hyperthermia-Ĥ.8.2. Quantification of dantrolene in body fluidsĤ.5.2.2 High-performance liquid chromatographyĤ.6. Identification and quantification of dantroleneĤ.5.2. Pharmaceutical formulation and synthesis 4.5. Name and chemical formula of antidote 4.3. Areas where there is insufficient information toģ.12.5. Other consequential or supportive therapy 3.12.4. Benzodiazepine overdose or intoxication 3.11. Clinical studies - clinical trials 3.10.1. Analysis of the toxic agent in biologicalģ.6. Quantification of the antidote in biologicalģ.5.3. Pharmaceutical formulation and synthesis 3.5. Name and chemical formula of antidote 3.3. Areas where there is insufficient informationĢ.12.5. Other consequential or supportive therapy 2.12.4. Effects in therapeutic use of opioids 2.10.2. Clinical studies - clinical trials 2.10.1. Pharmaceutical formulation and synthesis 2.5. Unit, Directorate-General Information Technologies and Industries,ġ. EUR 14797 EN of the Commission of the EuropeanĬommunities, Dissemination of Scientific and Technical Knowledge (c) World Health Organization, Geneva, 1993 and Might be made of the information contained in this report. Neither the Commission of the European Communities nor any personĪcting on behalf of the Commission is responsible for the use which World Health Organization in preference to others of a similar Products does not imply that they are endorsed or recommended by the The mention of specific companies or of certain manufacturers' Organization and of the Commission of the European Communities Published by Cambridge University Press on behalf of the World Health World Health Organization, Geneva, SwitzerlandĬommission of the European Communities, Luxembourg International Programme on Chemical Safety,

Ulleval University Hospital, Oslo, Norway Practical use to clinical toxicologists and all those involved in theĭepartment of Health, London, United Kingdom

#Hydromorphone antidote series

The series will thereforeĬollate a wealth of useful information which will be of immense This scientific assessment is complemented byĭetailed clinical information on routes of administration,Ĭontraindications, precautions and so on. Will greatly assist in the selection and administration of anĪppropriate antidote. TheĪim has been to provide an authoritative consensus statement which This series will therefore summarise and assess, on an antidote byĪntidote basis, their clinical use, mode of action and efficacy. Rigorous way the efficacy and use of a wide range of antidotes. To identify and evaluate for the first time in a scientific and

Undertaken a major programme to evaluate antidotes used clinically Of the European Communities (CEC) (ILO/UNEP/WHO) have jointly International Programme on Chemical Safety (IPCS) and the Commission Guidance on the use of antidotes to treat poisoning. This important new series will provide definitive and authoritative

Volume 2 Antidotes for poisoning by cyanide Volume 1 Naloxone, flumazenil and dantrolene as antidotes IPCS International Programme on Chemical SafetyĬEC Commission of the European Communities Naloxone, Flumazenil and Dantrolene as Antidotes IPCS/CEC EVALUATION OF ANTIDOTES SERIES VOLUME 1 NALOXONE, FLUMAZENIL AND DANTROLENE AS ANTIDOTES